icobrain ms

FDA & CE | Neuro | MRI | Amplifier Partner

Description of use

icobrain ms addresses the need for the early prediction of disability progression, relapses and treatment response in individual multiple sclerosis (MS) patients by helping physicians assess subclinical disease progression.

Objective assessment of the lesion dissemination in space and time by:

  • Detecting, quantifying and tracking the evolution of FLAIR lesions, black holes and contrast-enhancing lesions to evaluate disease activity.
  • Reporting the FLAIR lesion distribution following the McDonald criteria (juxtacortical, periventricular, deep white matter and infratentorial).

Precise and relevant brain atrophy measures by:

  • Tracking the annualized brain volume changes for whole brain and gray matter to evaluate disease progression.
  • Comparing brain volumes and volume changes to an age-and sex matched reference population.

The application content is provided by the respective AI vendors.